A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Clinical Trial Grant
Awarded By
BioMed Valley Discoveries
Start Date
December 15, 2020
End Date
August 7, 2025
Awarded By
BioMed Valley Discoveries
Start Date
December 15, 2020
End Date
August 7, 2025